Biopharma Innovation in Trouble

Regulators and sponsors are seeking more productive research strategies to alleviate the squeeze in R&D investment, writes Jill Wechsler.

Next year it will cost $2.2 million to submit an NDA or biologics license application (BLA) for FDA review, and $1 million for a supplement with clinical data, generally to support new indications or expanded labeling. Review of a new biosimilar application that carries clinical data will be just as costly. While a $2 million application fee may be relatively inconsequential for a large pharma company, it is a considerable amount for small firms with limited resources. The slight drop in anticipated NDAs that is expected to result in 2014 may reflect an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

FDA has a ways to go to approve as many new molecular entities (NMEs) in 2013 as the near-record 39 NMEs in 2012, and maintaining momentum will be harder in the future if initial submissions drop.

A more positive view of the approvals-and-innovative issue is to distinguish truly important NMEs-“first-in-class” and “advance-in-class” medicines that account for a growing proportion of new drugs-from “addition-to-class” drugs that are declining, according to FDA analysis. A rising number of advanced new therapies are coming to market, according to this assessment, even if total approvals remain static.

FDA’s new breakthrough drug program promises to support this shift by speeding the development and authorization of promising, critical therapies. Not only will FDA accelerate the review of applications for therapies that win the “breakthrough” designation, but agency scientists will provide advice and leeway to streamline clinical development. According to Friends of Cancer Research, a lead advocate for the program, FDA received 73 requests for breakthrough status as of late July-much more than the handful initially expected. The designation has been denied for 22 requests and granted for 25 experimental drugs that demonstrate early signs of clinical improvement over existing therapies for serious diseases, such as cancer and cystic fibrosis.

At the same time, there are clear challenges in bringing these innovative treatments to market. Insurers and health plans may hold off reimbursement until additional clinical data confirms efficacy and added benefits. Manufacturers also face problems in scaling up quickly to commercial production.

FDA advice for implementing this and other expedited review and development programs should help, as seen in a June draft guidance that offers sponsors insight into which factors lead to a breakthrough designation for a drug, plus accelerated testing and review. FDA also plans guidance on accelerating the development of diagnostics that can help sponsors demonstrate which patients respond to therapy. Pharma and biotech firms are happy to announce when an experimental product receives breakthrough or expedited designations, but there’s much less information out there on what FDA turns down-and why.